-
-
-
-
-
-
-
Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca
-
-
-
-
-
-
-
AstraZeneca says Fasenra misses main goal in COPD trial
-
-
-
-
-
-
-
AstraZeneca's Q1 2025 Financial Results
-
-
-
-
-
-
-
AstraZeneca’s 9M and Q3 2024 results
-
-
-
-
-
-
-
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
-
-
-
-
-
-
-
AstraZeneca (AZN) Completes Acquisition of Gracell Biotechnologies
-
-
-
-
-
-
-
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

